Garvan Text 09 1.Xpr
Total Page:16
File Type:pdf, Size:1020Kb
Garvan Institute of Medical Research Annual Report 2009 Contents ............................................................................................................................................................................................ Who we are, What we do 03 Garvan's mission is to make significant Reports contributions to medical research that will Chairman's Report 04 Executive Director's Report 06 change the directions of science and medicine Garvan Research Foundation Chairman's Report 08 and have major impacts on human health. Garvan at a Glance Research Collaborations 11 Garvan strives to enhance and develop research Patent Portfolio by Category 12 Scientific Publications 12 programs that combine fundamental science Philanthropic Support 12 Staff Profile 13 with strong clinical interactions. Operating Income 13 Peer Reviewed Grant Income 13 Organisation Chart 15 Research Highlights 17 Research Programs & Initiatives Cancer Program 18 The Kinghorn Cancer Centre 26 Diabetes & Obesity Program 28 Diabetes Vaccine Development Centre 34 Immunology Program 36 Neuroscience Program 44 Osteoporosis & Bone Biology Program 48 Core Research Facilities 53 Management Highlights 55 Business Development 57 Garvan Community Life Governors 58 Partners for the Future 58 Volunteers 58 Garvan Supporters 59 Bequests 61 Governance Institute Governance 63 Foundation Governance 66 Publications 71 Financial Highlights Income Statement 81 Balance Sheet 82 Garvan Research Foundation Statement of Funds 83 Who we are, What we do ............................................................................................................................................................................................ 03 The Garvan Institute of Medical Research is a world leader in its field, pioneering study into some of the most widespread diseases affecting our community today. Research at Garvan is focused upon understanding the role of genes in health and disease as the basis for developing future cures. Significant breakthroughs have been achieved by Garvan scientists in the understanding and treatment of diseases such as: _ Cancer _ Diabetes and obesity _ Alzheimer's and Parkinson's disease _ Osteoporosis _ Arthritis and asthma _ Pituitary disorders Garvan's ultimate goal is prevention and cure of these major diseases. Chairman’s Report CHAIRMAN’S REPORT ............................................................................................................................................................................................ ............................................................................................................................................................................................ 05 2009 We were particularly pleased to name the Centre The Kinghorn Cancer Centre: a joint facility of the Garvan Institute of Medical Research and St Vincent's Hospital I am pleased to report that Garvan continued its excellent record of research in recognition of a most generous donation of $25m from the Kinghorn Foundation. success in 2009, as measured by grants, publication impacts and international awards, and we are justly proud of our faculty and staff. Business Development Garvan's success in basic research continues to be matched by progress in Several important strategic initiatives were consolidated during the year, including: translating research “discoveries” into real outcomes for patients. _ Planning approval and funding for the new Garvan St Vincent's Cancer Centre _ Implementation of all the major recommendations arising from the Strategic 2009 saw excellent progress in several collaborations with the biotech industry. Review of the Institute completed by the international panel, and Positive early results were generated from the research collaboration with US west _ A highly successful first year of operations for Australian BioResources, our coast biotech, Kai Pharmaceuticals, to develop a potential Type 2 diabetes major breeding and holding facility for experimental mouse models in the therapeutic. This project is testing a molecule that may be effective in blocking Southern Highlands. "PKC epsilon" (PKCe), an enzyme that is active during diabetes and which reduces the availability of insulin. Financial Performance Garvan's operating income grew to approximately $64m in 2009 from $46m the Similarly the licence to Danish-based NsGene A/S of the hormone galanin which is previous year, an increase that is testament to the quality of Garvan research. being developed as an epilepsy therapy continued its progression towards phase 1 Philanthropic support through the Garvan Research Foundation, essential for clinical trials. Other exciting collaborations are detailed in this Annual Report. providing critical equipment and facilitating new initiatives, continued to be strong, with over $5.3m in general and specific grants contributed to research programs 2010 and almost $6.4m into the long term endowment of the Institute. Australia wide, medical research can proudly boast its continuing discovery record in Our People causes of, and potential cures for, many of the world's diseases. I take this opportunity Garvan has been very well served for many years by the commitment and counsel to add Garvan's thanks and congratulations to the extraordinary efforts of Elizabeth of an outstanding Board of Directors. There were several Board changes during Blackburn, Australia's most recent addition to its long list of Noble laureates. 2009 as longstanding members Graham Bradley and Professor Ron Trent resigned to be replaced by the incoming Chair of the Foundation, Geoff Dixon, and Dr John Given this performance, it is especially disappointing once again to be obliged to Horvath. During Graham Bradley's time as Chair of the Foundation for the past observe the appalling lack of funds in this State and in this country for the operating decade, the Endowment Fund grew from ~$4m to nearly $28m. We also welcomed support (often referred to as infrastructure funding) necessary to run the Anne Keating and Jillian Segal as nominees of the NSW Government and the laboratories. Scientists in universities and medical research institutes depend on University of New South Wales (UNSW) respectively. The Institute is most grateful success in the NHMRC research grants scheme for their salaries. But for every dollar for the contributions made by the outgoing directors. Lisa McIntyre, Chair of our of such grants we need about another 70c for day to day lab and Institute Business Development Advisory Council, and Peter Smith, Dean of Medicine at operating expenses. We, like all others in research, are currently relying on past UNSW, were both reappointed for a further term. I was also honoured to be endowments and current donations to find this 70c to keep the doors open. This is reappointed as a nominee of the Trustees of St Vincent's Hospital. not a long term solution for Garvan or the research platform of this nation. Garvan St Vincent's Cancer Centre The Board is confident that, with the support of government and the community, The mission of our Centre is to create a facility of international standing and best our research will continue to have a growing impact on human health, particularly as practice in translational cancer research which will accelerate the rate at which new we integrate it even more closely with health care delivery. discoveries can be trialled in the clinic. Once again my sincere thanks and admiration are extended to Professor John Shine, 2009 witnessed extraordinary and exciting progress for the Garvan St Vincent's his senior management team, faculty and staff. Cancer Centre. The architects (Bligh Voller Nield) completed the design work based on our detailed functional and design briefs and development approval was finally granted in late December. Importantly, we also received a $70m grant from the Federal Government's Health and Hospitals Fund and a $2.5m grant from the Australian Cancer Research Foundation; we also accumulated philanthropic support of nearly $40m plus the commitment of the land from the Trustees of St Vincent's Hospital. Together with the funds raised from the inspiring “Nuns Run” and the St Vincent's Garvan Gala Dinner, we were able to reach our goal of $110m needed for Bill Ferris AC the construction and fit-out of this important and innovative facility. The Centre Chairman should be ready for occupancy by early 2012. Garvan Institute of Medical Research Executive Director’s Report EXECUTIVE DIRECTOR’S REPORT ............................................................................................................................................................................................ ............................................................................................................................................................................................ 07 2009 Australian BioResources (ABR) The state-of-the-art holding and breeding facility for experimental mouse lines at 2009 was another very productive year for Garvan in terms of significant research Moss Vale provides critical infrastructure for Australian innovation. The facility findings, success in obtaining competitive grants and growth in the number of completed its first full year of operation in 2009, reaching 50% of total capacity papers accepted for publication in prestigious international journals. We published (approximately 25,000 mice). It now holds all major breeding colonies for